Trial Profile

An Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of ETI-204 Alone and in the Presence of Ciprofloxacin in Adult Volunteers

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Sep 2016 According to an Elusys Therapeutics media release, results from this study are published online at Clinical Therapeutics.
24 Aug 2016 Results assessing safety, immunogenicity, and pharmacokinetics of this and other four studies published in the Clinical Therapeutics.
21 Mar 2016 According to Elusys media release, the U.S. Food and Drug Administration (FDA) has approved ANTHIM (obiltoxaximab) Injection, the company's monoclonal antibody (mAb) anthrax antitoxin.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com